Primary aldosteronism with mild autonomous cortisol secretion increases renal complication risk.


Journal

European journal of endocrinology
ISSN: 1479-683X
Titre abrégé: Eur J Endocrinol
Pays: England
ID NLM: 9423848

Informations de publication

Date de publication:
25 Apr 2022
Historique:
received: 06 11 2021
accepted: 05 04 2022
pubmed: 6 4 2022
medline: 28 4 2022
entrez: 5 4 2022
Statut: epublish

Résumé

In primary aldosteronism (PA), renal impairment has been identified as an important comorbidity. Excess cortisol production also may lead to renal damage; thus, concomitant mild autonomous cortisol secretion (MACS) may predispose PA patients to renal disorders. However, there is limited evidence to support this claim. Therefore, this study aimed to determine whether the concurrence of MACS and PA increases the risk of renal complications. This study is a retrospective cross-sectional study. A total of 1310 patients with PA were stratified into two groups according to 1 mg dexamethasone suppression test (DST) results (cut-off post-DST serum cortisol 1.8 µg/dL): MACS (n = 340) and non-MACS (n = 970). The prevalence of renal complications was compared between the group. We also performed multiple logistic regression analysis to determine factors that increase the risk for renal complications. The prevalence of lowered estimated glomerular filtration rate (eGFR) and proteinuria was nearly twice higher in the MACS group than in the non-MACS group. Not only plasma aldosterone concentration (PAC) but also the presence of MACS was selected as independent factors that were associated with the two renal outcomes. The risk of lower eGFR or proteinuria in patients who had MACS and higher levels PAC was several folds higher than in those who had an absence of MACS and lower levels of PAC. MACS is an independent risk factor for renal complications in patients with PA, and MACS concomitant with higher aldosterone secretion in PA patients causes an increase in the risk of developing renal complications.

Identifiants

pubmed: 35380982
doi: 10.1530/EJE-21-1131
doi:

Substances chimiques

Aldosterone 4964P6T9RB
Hydrocortisone WI4X0X7BPJ

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

645-655

Auteurs

Takuyuki Katabami (T)

Division of Metabolism and Endocrinology, Department of Internal Medicine, St. Marianna University Yokohama City Seibu Hospital, Kanagawa, Japan.

Ren Matsuba (R)

Division of Metabolism and Endocrinology, Department of Internal Medicine, St. Marianna University Yokohama City Seibu Hospital, Kanagawa, Japan.

Hiroki Kobayashi (H)

Division of Nephrology, Hypertension, and Endocrinology, Nihon University School of Medicine, Tokyo, Japan.

Tomoko Nakagawa (T)

Division of Metabolism and Endocrinology, Department of Internal Medicine, St. Marianna University School of Medicine, Kanagawa, Japan.

Isao Kurihara (I)

Department of Endocrinology, Metabolism, and Nephrology, Keio University School of Medicine, Tokyo, Japan.
Department of Medical Education, National Defense Medical College, Saitama, Japan.

Takamasa Ichijo (T)

Department of Endocrinology and Diabetes, Saiseikai Yokohamashi Tobu Hospital, Kanagawa, Japan.

Mika Tsuiki (M)

Department of Endocrinology and Metabolism, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.

Norio Wada (N)

Department of Diabetes and Endocrinology, Sapporo City General Hospital, Hokkaido, Japan.

Yoshihiro Ogawa (Y)

Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Masakatsu Sone (M)

Division of Metabolism and Endocrinology, Department of Internal Medicine, St. Marianna University School of Medicine, Kanagawa, Japan.
Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Nobuya Inagaki (N)

Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Takanobu Yoshimoto (T)

Department of Molecular Endocrinology and Metabolism, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Diabetes and Endocrinology, Tokyo Metropolitan Hiroo Hospital, Tokyo, Japan.

Katsutoshi Takahashi (K)

Division of Metabolism, Showa General Hospital, Tokyo, Japan.

Koichi Yamamoto (K)

Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.

Shoichiro Izawa (S)

Division of Endocrinology and Metabolism, Tottori University Faculty of Medicine, Tottori, Japan.

Miki Kakutani (M)

Division of Diabetes, Endocrinology, and Clinical Immunology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan.

Akiyo Tanabe (A)

Division of Endocrinology, National Center for Global Health and Medicine, Tokyo, Japan.

Mitsuhide Naruse (M)

Endocrine Center, Ijinkai Takeda General Hospital and Clinical Research Center, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH